Interestingly, 3AC treatment de-stabilizes SHIP1 protein expression via the Ubiquitin-proteasome system, but not SHIP2, in multiple myeloma cells, providing further evidence of its selectivity [19]. Here, INPP5D is linked to plasma cell myeloma.